Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells 33,561 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 33,561 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the transaction, the director owned 31,596 shares of the company’s stock, valued at $9,478,800. This trade represents a 51.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

CRL traded up $1.84 during midday trading on Thursday, reaching $296.94. 900,812 shares of the company’s stock were exchanged, compared to its average volume of 927,534. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $303.31. The stock has a market capitalization of $14.18 billion, a PE ratio of -61.22, a P/E/G ratio of 3.08 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The business’s 50-day moving average price is $241.70 and its 200 day moving average price is $195.88.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same period in the prior year, the business earned $3.12 earnings per share. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Higher long-term earnings outlook: Zacks Research raised its FY2026 EPS estimate to $11.15 from $10.91, FY2027 to $12.49 from $12.11, and FY2028 to $13.82 from $13.01. The firm also increased estimates for Q2 2027 and Q3 2027, suggesting stronger expected earnings momentum beyond the current quarter. MarketBeat Charles River Laboratories stock page
• Positive Sentiment: New vaccine partnership: Medigen linked up with Charles River in an effort to take an enterovirus vaccine global. The collaboration could support future contract research and development activity, although financial details were not disclosed. Medigen links up with Charles River in push to take enterovirus vaccine global
• Neutral Sentiment: Current earnings backdrop: Charles River recently exceeded quarterly EPS and revenue expectations, reporting $3.02 in EPS and approximately $1.0 billion in revenue. However, revenue declined 2.7% year over year, and the company’s current full-year consensus EPS estimate remains $11.35. MarketBeat Charles River Laboratories stock page
• Negative Sentiment: Some near-term estimate cuts: Zacks lowered its Q3 2026 EPS estimate to $2.94 from $2.98, Q4 2026 to $3.13 from $3.15, Q1 2027 to $2.56 from $2.58, and Q4 2027 to $3.40 from $3.43. These reductions indicate some pressure on the company’s nearer-term earnings trajectory.

Hedge Funds Weigh In On Charles River Laboratories International

A number of large investors have recently modified their holdings of CRL. HighTower Advisors LLC grew its holdings in shares of Charles River Laboratories International by 5.7% during the 2nd quarter. HighTower Advisors LLC now owns 3,781 shares of the medical research company’s stock worth $857,000 after purchasing an additional 203 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Charles River Laboratories International in the second quarter valued at approximately $3,855,000. California State Teachers Retirement System raised its holdings in Charles River Laboratories International by 22,535.2% in the second quarter. California State Teachers Retirement System now owns 12,895,733 shares of the medical research company’s stock valued at $2,924,623,000 after buying an additional 12,838,761 shares during the period. Raiffeisen Bank International AG lifted its position in Charles River Laboratories International by 9.1% during the second quarter. Raiffeisen Bank International AG now owns 6,000 shares of the medical research company’s stock valued at $1,353,000 after buying an additional 500 shares in the last quarter. Finally, Knollwood Investment Advisory LLC acquired a new position in Charles River Laboratories International during the second quarter valued at approximately $225,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CRL. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Morgan Stanley upped their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Royal Bank Of Canada increased their price objective on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.